Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
World Journal of Pediatrics
Erschienen in: World Journal of Pediatrics 3/2024

07.09.2023 | Commentary

Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts’ consensus statement updated for the Omicron variant

verfasst von: Rong-Meng Jiang, Zheng-De Xie, Yi Jiang, Xiao-Xia Lu, Run-Ming Jin, Yue-Jie Zheng, Yun-Xiao Shang, Bao-Ping Xu, Zhi-Sheng Liu, Gen Lu, Ji-Kui Deng, Guang-Hua Liu, Xiao-Chuan Wang, Jian-She Wang, Lu-Zhao Feng, Wei Liu, Yi Zheng, Sai-Nan Shu, Min Lu, Wan-Jun Luo, Miao Liu, Yu-Xia Cui, Le-Ping Ye, A-Dong Shen, Gang Liu, Li-Wei Gao, Li-Juan Xiong, Yan Bai, Li-Kai Lin, Zhuang Wei, Feng-Xia Xue, Tian-You Wang, Dong-Chi Zhao, Jian-Bo Shao, Daniel Kwok-keung Ng, Gary Wing-kin Wong, Zheng-Yan Zhao, Xing-Wang Li, Yong-Hong Yang, Kun-Ling Shen

Erschienen in: World Journal of Pediatrics | Ausgabe 3/2024

Einloggen, um Zugang zu erhalten

Excerpt

It has been more than 3 years since the novel coronavirus (SARS-CoV-2) pandemic raged globally. The coronavirus disease 2019 (COVID-19) has greatly influenced human society. According to data from the World Health Organization (WHO), there were over 656 million confirmed cases of COVID-19 in the world as of January 1, 2023, including over 6.6 million deaths [1]. In the first year of the SARS-CoV-2 pandemic, the epidemic strains were mainly the original strain, Alpha, Beta, and Gamma variants spreading all over the world. The Delta variant has taken dominance after December 2020. Since November 2021, the Omicron variants, including B.1.1.529, BA1, BA2, BA4, and BA5 variants have emerged with increased infectivity, shortened incubation period, and enhanced immune escape ability, but decreased pathogenicity, resulting in a new round of global epidemic outbreak, and a significant increase in the infection rate of children. Since October 2022, the Omicron subvariants, such as BF.7, BQ.1, and BQ.1.1, as well as the recombinant strains (XBB) with stronger immune escape ability and infectious ability have increased rapidly, and have replaced BA.5.2 as the dominant variants in several countries and areas. According to the surveillance data of the Chinese Center for Disease Control and Prevention, the current circulating strains in China are mainly BA.5.2 and BF.7, which are the sub-lineage of BA.5 [2]. …
Literatur
1.
2.
3.
4.
5.
Jiang RM, Xie ZD, Jiang Y, Lu XX, Jin RM, Zheng YJ, et al. Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts’ consensus statement (fourth edition). Chin J Appl Clin Pediatr. 2022;37:1053–65 (In Chinese).
6.
7.
8.
9.
10.
Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature. 2022;608:603–8.PubMedPubMedCentralCrossRef
11.
Aboubakr HA, Sharafeldin TA, Goyal SM. Stability of SARS-CoV-2 and other coronaviruses in the environment and on common touch surfaces and the influence of climatic conditions: a review. Transbound Emerg Dis. 2021;68:296–312.PubMedCrossRef
12.
Ren SY, Wang WB, Hao YG, Zhang HR, Wang ZC, Chen YL, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases. 2020;8:1391–9.PubMedPubMedCentralCrossRef
13.
van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020;382:1564–7.PubMedCrossRef
14.
Hirose R, Itoh Y, Ikegaya H, Miyazaki H, Watanabe N, Yoshida T, et al. Differences in environmental stability among SARS-CoV-2 variants of concern: both omicron BA.1 and BA.2 have higher stability. Clin Microbiol Infect. 2022;28:1486–91.PubMedPubMedCentralCrossRef
15.
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271-80.e8.PubMedPubMedCentralCrossRef
16.
Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G, et al. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9:1417.PubMedPubMedCentralCrossRef
17.
Ren X, Wen W, Fan X, Hou W, Su B, Cai P, et al. COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas. Cell. 2021;184:1895-913.e19.PubMedPubMedCentralCrossRef
18.
Hu B, Chan JF, Liu H, Liu Y, Chai Y, Shi J, et al. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2. Emerg Microbes Infect. 2022;11:2275–87.PubMedPubMedCentralCrossRef
19.
Meng B, Abdullahi A, Ferreira IATM, Goonawardane N, Saito A, Kimura I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–14.PubMedPubMedCentralCrossRef
20.
Machado-Curbelo C, Gutiérrez-Gil J, González-Quevedo A. A shift in SARS-CoV-2 Omicron variant’s entry pathway might explain different clinical outcomes. MEDICC Rev. 2022;24:68–71.PubMedCrossRef
21.
22.
Chi H, Chang L, Chao YC, Lin DS, Yang HW, Fang LC, et al. Pathogenesis and preventive tactics of immune-mediated non-pulmonary COVID-19 in children and beyond. Int J Mol Sci. 2022;23:14157.PubMedPubMedCentralCrossRef
23.
24.
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020;370:eabd4570.PubMedPubMedCentralCrossRef
25.
Bastard P, Gervais A, Le Voyer T, Rosain J, Philippot Q, Manry J, et al. Autoantibodies neutralizing type I IFNs are present in -4% of uninfected individuals over 70 years old and account for -20% of COVID-19 deaths. Sci Immunol. 2021;6:eabl4340.PubMedPubMedCentralCrossRef
26.
Deshmukh V, Motwani R, Kumar A, Kumari C, Raza K. Histopathological observations in COVID-19: a systematic review. J Clin Pathol. 2021;74:76–83.PubMedCrossRef
27.
Calabrese F, Pezzuto F, Fortarezza F, Hofman P, Kern I, Panizo A, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists. Virchows Arch. 2020;477:359–72.PubMedPubMedCentralCrossRef
28.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.PubMedCrossRef
29.
Menger J, Apostolidou S, Edler C, Kniep I, Kobbe R, Singer D, et al. Fatal outcome of SARS-CoV-2 infection (B1.1.7) in a 4-year-old child. Int J Legal Med. 2022;136:189–92.PubMedCrossRef
30.
Nomura E, Finn LS, Bauer A, Rozansky D, Iragorri S, Jenkins R, et al. Pathology findings in pediatric patients with COVID-19 and kidney dysfunction. Pediatr Nephrol. 2022;37:2375–81.PubMedPubMedCentralCrossRef
31.
Gomes I, Karmirian K, Oliveira JT, Pedrosa CDSG, Mendes MA, Rosman FC, et al. SARS-CoV-2 infection of the central nervous system in a 14-month-old child: a case report of a complete autopsy. Lancet Reg Health Am. 2021;2:100046.PubMedPubMedCentral
32.
Duarte-Neto AN, Caldini EG, Gomes-Gouvêa MS, Kanamura CT, de Almeida Monteiro RA, Ferranti JF, et al. An autopsy study of the spectrum of severe COVID-19 in children: from SARS to different phenotypes of MIS-C. EClinicalMedicine. 2021;35:100850.PubMedPubMedCentralCrossRef
33.
Goussard P, Schubert P, Parker N, Myburgh C, Rabie H, van der Zalm MM, et al. Fatal SARS-CoV-2 Omicron variant in a young infant: autopsy findings. Pediatr Pulmonol. 2022;57:1363–5.PubMedPubMedCentralCrossRef
34.
Ji TY, Jiang YW. Pay attention to the nervous system involvement in SARS-CoV-2 infection in children. Chin J Pediatr. 2023;61:100–3 (In Chinese).
35.
Expert Group on Intensive Care for SARS-CoV-2 Infection, Beijing Children′s Hospital, Capital Medical University, National Center for Children′s Health, Beijing Municipal Expert Group on Medical Treatment of SARS-CoV-2 Infection for Children. Recommendations for early identification, diagnosis and treatment of severe SARS-CoV-2 infection in children. Chin J Pediatr. 2023;61:199–202 (In Chinese).
36.
Liguoro I, Pilotto C, Bonanni M, Ferrari ME, Pusiol A, Nocerino A, et al. SARS-COV-2 infection in children and newborns: a systematic review. Eur J Pediatr. 2020;179:1029–46.PubMedPubMedCentralCrossRef
37.
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American college of rheumatology clinical guidance for multisystem inflammatory syndrome in children associated with SARS-CoV-2 and hyperinflammation in pediatric COVID-19: version 3. Arthritis Rheumatol. 2022;74:e1-20.PubMedPubMedCentralCrossRef
38.
Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, Rodriguez-Villalobos H, et al. Low performance of rapid antigen detection test as frontline testing for COVID-19 diagnosis. J Clin Virol. 2020;129:104455.PubMedPubMedCentralCrossRef
39.
Chinese Society of Radiology, Chinese Medical Association. Radiological diagnosis of COVID-19:expert recommendation from the Chinese society of radiology (First edition). Chin J Radiol. 2020;54:279–85 (In Chinese).
40.
Ma HJ, Shao JB, Wang YJ, Zai AG, Zheng NN, Li Q, et al. High resolution CT features of COVID-19 in children. Chin J Radiol. 2020;54:310–3 (In Chinese).
41.
Ma H, Hu J, Tian J, Zhou X, Li H, Laws MT, et al. A single-center, retrospective study of COVID-19 features in children: a descriptive investigation. BMC Med. 2020;18:123.PubMedPubMedCentralCrossRef
42.
Peng X, Guo Y, Xiao H, Xia W, Zhai A, Zhu B, et al. Overview of chest involvement at computed tomography in children with coronavirus disease 2019 (COVID-19). Pediatr Radiol. 2021;51:222–30.PubMedCrossRef
43.
Akl EA, Blažić I, Yaacoub S, Frija G, Chou R, Appiah JA, et al. Use of chest imaging in the diagnosis and management of COVID-19: a WHO rapid advice guide. Radiology. 2021;298:E63–9.PubMedCrossRef
44.
Rubin GD, Ryerson CJ, Haramati LB, Sverzellati N, Kanne JP, Raoof S, et al. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the fleischner society. Radiology. 2020;296:172–80.PubMedCrossRef
45.
Afshar-Oromieh A, Prosch H, Schaefer-Prokop C, Bohn KP, Alberts I, Mingels C, et al. A comprehensive review of imaging findings in COVID-19—status in early 2021. Eur J Nucl Med Mol Imaging. 2021;48:2500–24.PubMedPubMedCentralCrossRef
46.
Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts’ consensus statement. World J Pediatr. 2020;16:223–31.PubMedPubMedCentralCrossRef
47.
Woodruff RC, Campbell AP, Taylor CA, Chai SJ, Kawasaki B, Meek J, et al. Risk factors for severe COVID-19 in children. Pediatrics. 2022;149:e2021053418.PubMedCrossRef
48.
49.
Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021;4:e2111182.PubMedPubMedCentralCrossRef
50.
Wanga V, Gerdes ME, Shi DS, Choudhary R, Dulski TM, Hsu S, et al. Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19—six hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1766–72.PubMedPubMedCentralCrossRef
51.
Nachega JB, Sam-Agudu NA, Machekano RN, Rabie H, van der Zalm MM, Redfern A, et al. Assessment of clinical outcomes among children and adolescents hospitalized With COVID-19 in 6 Sub-Saharan African countries. JAMA Pediatr. 2022;176:e216436.PubMedPubMedCentralCrossRef
52.
Fernandes DM, Oliveira CR, Guerguis S, Eisenberg R, Choi J, Kim M, et al. Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in Hospitalized children and youth. J Pediatr. 2021;230:23–31.PubMedCrossRef
53.
Bailey LC, Razzaghi H, Burrows EK, Bunnell HT, Camacho PEF, Christakis DA, et al. Assessment of 135794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr. 2021;175:176–84.PubMedCrossRef
54.
Williams N, Radia T, Harman K, Agrawal P, Cook J, Gupta A. COVID-19 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. Eur J Pediatr. 2021;180:689–97.PubMedCrossRef
55.
McCormick DW, Richardson LC, Young PR, Viens LJ, Gould CV, Kimball A, et al. Deaths in children and adolescents associated with COVID-19 and MIS-C in the United States. Pediatrics. 2021;148:e2021052273.PubMedCrossRef
56.
Tripathi S, Christison AL, Levy E, McGravery J, Tekin A, Bolliger D, et al. The impact of obesity on disease severity and outcomes among hospitalized children with COVID-19. Hosp Pediatr. 2021;11:e297-316.PubMedCrossRef
57.
Zhou B, Yuan Y, Wang S, Zhang Z, Yang M, Deng X, et al. Risk profiles of severe illness in children with COVID-19: a meta-analysis of individual patients. Pediatr Res. 2021;90:347–52.PubMedPubMedCentralCrossRef
58.
Tang L, Gu S, Gong Y, Li B, Lu H, Li Q, et al. Clinical significance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering (Beijing). 2020;6:1178–84.PubMed
59.
Chinese Medical Association Clinical Medicine Association. Expert consensus on rational drug use of aerotom inhalation therapy (2019 edition). Medical Guide. 2019;38:135–46.
60.
Shen K, Hong J, El Beleidy A, Furman E, Liu H, Yin Y, et al. International expert opinion on the use of nebulization for pediatric asthma therapy during the COVID-19 pandemic. J Thorac Dis. 2021;13:3934–47.PubMedPubMedCentralCrossRef
61.
Martens K, Vanhulle E, Viskens A, Hellings PW, Vermeire K. Fluticasone propionate suppresses the SARS-CoV-2 induced increase in respiratory epithelial permeability in vitro. Rhinology. 2023;61:161–9.PubMed
62.
Shen KL, Shang YX, Zhang H, Liu CS, Yang QZ, Chen YJ, et al. A multicenter randomized controlled clinical study on the efficacy and safety of recombinant human interferon α2b spray (Pputida) in treatment of acute upper respiratory tract infections in children. Chin J Pract Pediatr. 2019;34:1010–6 (In Chinese).
63.
Xu YL, Li Y, Chen YP, Xin SX, Xie L, Liang YD, et al. A multicenter controlled clinical study on the efficacy and safety of recombinant human interferon α2b spray in the treatment of hand, foot and mouth disease in children. Chin J Infect Dis. 2018;36:101–6 (In Chinese).
64.
Ye YZ, Dou YL, Hao JH, Zhou L, Lin AW, Wang SN, et al. Efficacy and safety of interferon α-2b spray for herpangina in children: a randomized, controlled trial. Int J Infect Dis. 2021;107:62–8.PubMedCrossRef
65.
Bhushan BLS, Wanve S, Koradia P, Bhomia V, Soni P, Chakraborty S, et al. Efficacy and safety of pegylated interferon-alpha2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study. Int J Infect Dis. 2021;111:281–7.CrossRef
66.
Zhou Q, MacArthur MR, He X, Wei X, Zarin P, Hanna BS, et al. Interferon-alpha2b treatment for COVID-19 Is associated with improvements in lung abnormalities. Viruses. 2020;13:44.PubMedPubMedCentralCrossRef
67.
68.
69.
Zhao JP, Hu Y, Du RH, Cheng ZS, Jin Y, Zhou M, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin J Tuberc Respir Dis. 2020;43:183–4 (In Chinese).
70.
Li ZR, Gao ZC, Gong PH. Advances in anti-inflammatory treatment of severe patients with coronavirus disease 2019. Chin J Respir Crit Care Med. 2021;20:64–9 (In Chinese).
71.
Endoscopy Committee, Pediatric Section of Chinese Medical Doctor Association, Pediatric Respiratory Endoscopy Committee, Endoscopists Section of Chinese Medical Doctor Association, Bronchoscopy Collaboration Subgroup of Respirology Group, Pediatric Section of Chinese Medical Association, Pediatric Interventional Respirology Group, Maternal and Pediatric Minimally Invasive Section of Chinese Maternal and Child Health Association. Recommendations on the pediatric flexible bronchoscopy during the outbreak of Severe Acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in China (trial edition). Chin J Appl Clin Pediatr. 2020;35:92–6 (In Chinese).
72.
73.
Zhuang SX, Huang GY. Advance on early diagnosis and treatment of fulminant myocarditis in children. Chin Pediatr Emerg Med. 2019:777–8 (In Chinese)
74.
Harwood R, Allin B, Jones CE, Whittaker E, Ramnarayan P, Ramanan AV, et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc Health. 2021;5:133–41.PubMedCrossRef
75.
Abrams JY, Belay ED, Godfred-Cato S, Campbell AP, Zambrano LD, Kunkel A, et al. Trends in treatments for multisystem inflammatory syndrome in children (MIS-C), United States, february 2020—July 2021. Clin Infect Dis. 2022;75:1201–9.PubMedCrossRef
76.
77.
Deep A, Bansal M, Ricci Z. Acute kidney injury and special considerations during renal replacement therapy in children with coronavirus disease-19: perspective from the critical care nephrology section of the European society of paediatric and neonatal intensive care. Blood Purif. 2021;50:150–60.PubMedCrossRef
78.
Gupta S, Coca SG, Chan L, Melamed ML, Brenner SK, Hayek SS, et al. AKI treated with renal replacement therapy in critically Ill patients with COVID-19. J Am Soc Nephrol. 2021;32:161–76.PubMedCrossRef
79.
80.
Xu W, Tang J, Chen C, Wang C, Wen W, Cheng Y, et al. Safety and efficacy of the COVID-19 vaccine in children and/or adolescents: a meta-analysis. J Infect. 2022;84:722–46.PubMedPubMedCentralCrossRef
81.
Castelli JM, Rearte A, Olszevicki S, Voto C, Del Valle JM, Pesce M, et al. Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. BMJ. 2022;379:e73070.
82.
Mu X, Cohen CA, Leung D, Rosa Duque JS, Cheng SMS, Chung Y, et al. Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents. Signal Transduct Target Ther. 2022;7:397.PubMedPubMedCentralCrossRef
83.
Khan FL, Nguyen JL, Singh TG, Puzniak LA, Wiemken TL, Schrecker JP, et al. Estimated BNT162b2 vaccine effectiveness against infection with delta and omicron variants among US children 5 to 11 years of age. JAMA Netw Open. 2022;5:e2246915.PubMedPubMedCentralCrossRef
84.
Wang L, Wu Z, Ying Z, Li M, Hu Y, Shu Q, et al. Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents. Nat Commun. 2022;13:6952.PubMedPubMedCentralCrossRef
Metadaten
Titel
Diagnosis, treatment and prevention of severe acute respiratory syndrome coronavirus 2 infection in children: experts’ consensus statement updated for the Omicron variant
verfasst von
Rong-Meng Jiang
Zheng-De Xie
Yi Jiang
Xiao-Xia Lu
Run-Ming Jin
Yue-Jie Zheng
Yun-Xiao Shang
Bao-Ping Xu
Zhi-Sheng Liu
Gen Lu
Ji-Kui Deng
Guang-Hua Liu
Xiao-Chuan Wang
Jian-She Wang
Lu-Zhao Feng
Wei Liu
Yi Zheng
Sai-Nan Shu
Min Lu
Wan-Jun Luo
Miao Liu
Yu-Xia Cui
Le-Ping Ye
A-Dong Shen
Gang Liu
Li-Wei Gao
Li-Juan Xiong
Yan Bai
Li-Kai Lin
Zhuang Wei
Feng-Xia Xue
Tian-You Wang
Dong-Chi Zhao
Jian-Bo Shao
Daniel Kwok-keung Ng
Gary Wing-kin Wong
Zheng-Yan Zhao
Xing-Wang Li
Yong-Hong Yang
Kun-Ling Shen
Publikationsdatum
07.09.2023
Verlag
Springer Nature Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 3/2024
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-023-00745-3

Weitere Artikel der Ausgabe 3/2024

World Journal of Pediatrics 3/2024 Zur Ausgabe

Editorial

Insights into postural orthostatic tachycardia syndrome after COVID-19 in pediatric patients

Original Article

Development and validation of a nomogram to predict allograft survival after pediatric liver transplantation

Review Article

Modeling tuberous sclerosis complex with human induced pluripotent stem cells

Meta-analysis

Comparative efficacy and optimal duration of first-line antibiotic regimens for acute otitis media in children and adolescents: a systematic review and network meta-analysis of 89 randomized clinical trials

Research Letter

Safety and efficacy of omalizumab for antihistamine-resistant chronic urticaria in children: a case series and literature review

Original Article

Proteomic profiling of cerebrospinal fluid in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease

Neu im Fachgebiet Pädiatrie

Ähnliche Überlebensraten nach Reanimation während des Transports bzw. vor Ort

29.05.2024 Reanimation im Kindesalter Nachrichten

Laut einer Studie aus den USA und Kanada scheint es bei der Reanimation von Kindern außerhalb einer Klinik keinen Unterschied für das Überleben zu machen, ob die Wiederbelebungsmaßnahmen während des Transports in die Klinik stattfinden oder vor Ort ausgeführt werden. Jedoch gibt es dabei einige Einschränkungen und eine wichtige Ausnahme.

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Begünstigt Bettruhe der Mutter doch das fetale Wachstum?

24.05.2024 Pränatale und perinatale Diagnostik Nachrichten

Ob ungeborene Kinder, die kleiner als die meisten Gleichaltrigen sind, schneller wachsen, wenn die Mutter sich mehr ausruht, wird diskutiert. Die Ergebnisse einer US-Studie sprechen dafür.

Bei Amblyopie früher abkleben als bisher empfohlen?

22.05.2024 Fehlsichtigkeit Nachrichten

Bei Amblyopie ist das frühzeitige Abkleben des kontralateralen Auges in den meisten Fällen wohl effektiver als der Therapiestandard mit zunächst mehrmonatigem Brilletragen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise